Haemonetics Corporation (NYSE:HAE) Sees Significant Decline in Short Interest

Haemonetics Corporation (NYSE:HAE) was the target of a significant drop in short interest in the month of January. As of January 30th, there was short interest totaling 2,411,300 shares, a drop of 21.7% from the January 15th total of 3,077,776 shares. Currently, 5.3% of the company’s stock are sold short. Based on an average daily trading volume, of 926,738 shares, the days-to-cover ratio is currently 2.6 days. Based on an average daily trading volume, of 926,738 shares, the days-to-cover ratio is currently 2.6 days. Currently, 5.3% of the company’s stock are sold short.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HAE. Schonfeld Strategic Advisors LLC bought a new stake in Haemonetics in the 4th quarter worth approximately $747,000. AQR Capital Management LLC boosted its stake in shares of Haemonetics by 48.6% in the 4th quarter. AQR Capital Management LLC now owns 3,163,104 shares of the medical instruments supplier’s stock worth $253,523,000 after buying an additional 1,034,226 shares during the last quarter. Abel Hall LLC purchased a new position in shares of Haemonetics in the 4th quarter worth $251,000. Trexquant Investment LP grew its holdings in shares of Haemonetics by 14.5% in the fourth quarter. Trexquant Investment LP now owns 125,524 shares of the medical instruments supplier’s stock worth $10,061,000 after acquiring an additional 15,879 shares during the period. Finally, Amundi purchased a new stake in Haemonetics during the fourth quarter valued at $222,000. Institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Up 1.4%

HAE traded up $0.82 during trading on Tuesday, hitting $58.58. 736,682 shares of the company’s stock traded hands, compared to its average volume of 1,044,252. The stock has a market capitalization of $2.72 billion, a price-to-earnings ratio of 16.14, a PEG ratio of 1.21 and a beta of 0.28. The company’s 50 day simple moving average is $73.40 and its two-hundred day simple moving average is $64.21. Haemonetics has a 12-month low of $47.31 and a 12-month high of $87.32. The company has a current ratio of 1.75, a quick ratio of 1.15 and a debt-to-equity ratio of 1.01.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.The firm had revenue of $338.97 million for the quarter, compared to the consensus estimate of $331.90 million. During the same period in the prior year, the company posted $1.19 earnings per share. The company’s quarterly revenue was down 2.7% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. Analysts predict that Haemonetics will post 4.55 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Mizuho dropped their price objective on shares of Haemonetics from $90.00 to $80.00 and set an “outperform” rating on the stock in a research note on Friday, February 6th. Needham & Company LLC cut Haemonetics from a “buy” rating to a “hold” rating in a research report on Monday, December 15th. BTIG Research restated a “buy” rating and issued a $88.00 price target on shares of Haemonetics in a research note on Friday, February 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haemonetics in a research report on Monday, December 29th. Finally, CJS Securities raised Haemonetics to a “strong-buy” rating in a report on Thursday, December 11th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $84.44.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.